Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

The Metabolic Effects of Consuming Sugar-Sweetened Beverages for Two Weeks (DRS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01103921
Recruitment Status : Completed
First Posted : April 15, 2010
Last Update Posted : May 30, 2017
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
University of California, Davis

Brief Summary:
The purpose of this study is to examine the effects of consumption of sugar-sweetened beverages on blood triglycerides and cholesterol, cholesterol concentrations, and the body's sensitivity to insulin.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome Insulin Resistance Dyslipidemia Other: Glucose Other: Fructose Other: High-Fructose Corn Syrup Other: No sugar (Aspartame) Not Applicable

Detailed Description:
The study is designed as a prospective, blinded diet intervention study during which the participants consume either fructose- or HFCS-sweetened beverages (providing 10%, 17.5% or 25% of energy) with meals. In addition, there will be two control groups, with one group consuming 0% sugar beverages sweetened with sucralose and the other consuming glucose-sweetened beverages at 25% of energy requirement. Experimental procedures, including 24-hour serial blood sampling, post-heparin infusions, gluteal biopsies, Magnetic Resonance Imaging of the liver and the abdomen, and Oral Glucose Tolerance and Disposal Tests, are performed during baseline and at the end of a 2-week intervention period at the UC Davis Clinical and Translational Science Center (CTSC) Clinical Research Center (CCRC). During the inpatient periods, subjects are served energy balanced diets. The diets provide 15% of energy as protein, 30% as fat, and 55% as carbohydrate. During baseline testing, the carbohydrate content consists primarily of complex carbohydrate (>97%). During intervention the 55% carbohydrate will consist of 10% sugar/45% complex, 17.5% sugar/37.5% complex, or 25% sugar/30% complex depending on the diet group to which the subject is assigned. During the outpatient intervention periods, the subjects reside at home and are provided with fructose- or HFCS -sweetened beverages that are consumed with each meal along with a self-selected ad libitum (usual) diet.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 214 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Basic Science
Official Title: Effects of 2-weeks Fructose & HFCS Consumption on Dyslipidemia & Insulin Resistance
Study Start Date : October 2008
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Fructose

Arm Intervention/treatment
Glucose Other: Glucose
25% dose at 2-week intervention assigned to subjects.
Other Name: Sugar

Fructose Other: Fructose
25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
Other Name: Sugar

High-Fructose Corn Syrup Other: High-Fructose Corn Syrup
25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
Other Name: HFCS

No sugar
Other: No sugar (Aspartame)
0% dose at 2-week intervention assigned to subjects.
Other Name: Non-caloric sweetener

Primary Outcome Measures :
  1. 24-hour triglyceride area under the curve [ Time Frame: Baseline and 2-week intervention ]
    32 serial blood samples are collected over a 24 hour period.

Secondary Outcome Measures :
  1. Insulin sensitivity index [ Time Frame: Baseline and 2-week intervention ]
    Insulin sensitivity is assessed using the deuterated glucose disposal method.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body mass index between 18-35
  • Self report of stable body weight during the past six months

Exclusion Criteria:

  • Diabetes Mellitus
  • Evidence of liver disorder
  • Evidence of kidney disorder
  • Evidence of thyroid disorder
  • Systolic blood pressure consistently over 160mmHg or diastolic blood pressure over 900mmHg
  • Triglycerides > 400mg/dl
  • LDL-C > 240mg/dl
  • Hemoglobin < 8.5 g/dl
  • Current, prior (within 2 months), or anticipated use of any hypolipidemic or anti-diabetic agents
  • Use of Selective Serotonin Reuptake Inhibitors and anti-hypertensive medications
  • Any other condition that, in the opinion of the investigators, would put subject at risk
  • Strenuous exerciser
  • Pregnant or lactating women
  • Smoker
  • Diet exclusions: food allergies, special dietary restrictions, habitual ingest of >2 alcoholic beverages/day

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01103921

Layout table for location information
United States, California
Clinical Research Center
Sacramento, California, United States, 95655
Sponsors and Collaborators
University of California, Davis
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
Principal Investigator: Peter J Havel, D.V.M University of California, Davis
Study Director: Kimber L Stanhope, Ph.D, R.D. University of California, Davis
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of California, Davis Identifier: NCT01103921    
Other Study ID Numbers: 200715772
R01HL091333 ( U.S. NIH Grant/Contract )
R01HL107256 ( U.S. NIH Grant/Contract )
First Posted: April 15, 2010    Key Record Dates
Last Update Posted: May 30, 2017
Last Verified: May 2017
Keywords provided by University of California, Davis:
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Lipid Metabolism Disorders